IL2 and neoplasm: While these observations are not conclusive, the modulation of tumour permissive IL17 along with other cytokines (IL2/IL21), which stimulate T cell proliferation, supports a significant contribution of immune-based mechanisms to the clinical efficacy of this regimen.27–30